{"id":57761,"date":"2023-07-18T13:04:11","date_gmt":"2023-07-18T11:04:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/"},"modified":"2023-07-18T13:04:11","modified_gmt":"2023-07-18T11:04:11","slug":"namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/","title":{"rendered":"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe"},"content":{"rendered":"
\n

TOLEDO, Ohio & MUNICH–(BUSINESS WIRE)–#CRO<\/a>—NAMSA<\/a>, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of CRI – The Clinical Research Institute<\/a>, a German-based full service CRO.<\/p>\n

<\/a>
<\/a><\/p>\n

\nFounded in 2011, CRI\u2019s mission is to provide the European MedTech market complete clinical research solutions<\/a> to accelerate scientific outcomes to their clients. Their team of researchers utilize their vast expertise across all areas of clinical research and cutting-edge data solutions to support their customers across the clinical research continuum.<\/p>\n

\n\u201cWe are delighted to welcome CRI to NAMSA,\u201d said Dr. Christophe Berthoux<\/a>, NAMSA CEO. \u201cThe addition of this organization to the NAMSA family is a significant move for us in Germany that enhances and expands our CRO offerings throughout Europe and across all markets. This exciting acquisition presents new opportunities for us to fulfill our mission of saving patients’ lives,\u201d Dr. Berthoux concluded.<\/p>\n

\nNAMSA\u2019s clinical research services<\/a> include clinical study management, post market studies, biostatistics and data management, safety reporting and imaging core lab services. Our clinical research teams are comprised of the MedTech industry\u2019s foremost experts, with experiences that span every manner of technology, therapy, indication and geography for clinical research. This broad range of experience allows NAMSA\u2019s teams to lead our clients through all phases of clinical research: from first in human to pivotal and post-market studies.<\/p>\n

\n\u201cCRI is an unmatched partner for NAMSA, as both companies share identical values and are wholeheartedly committed to delivering unparalleled service and resources to the medical device and diagnostic sectors,\u201d declared Dr. Thomas Fetsch<\/a>, CRI CEO. \u201cWith a team of seasoned experts well versed in the fields of medicine and science, CRI is thrilled to join forces with NAMSA to bolster their global presence, particularly in Europe,\u201d Dr. Fetsch concluded.<\/p>\n

\n\u201cTogether, the collective proficiency of both organizations will establish them as the foremost MedTech CRO for Cardiovascular research<\/a> services across the globe,\u201d stated Elisabeth Freund, CRI Founder. \u201cI am confident in the abilities of our teams to leverage expertise and continue to deliver superior results to our global clients.\u201d<\/p>\n

\nThe price and terms of the transaction are undisclosed.<\/p>\n

\nNAMSA is an ARCHIMED<\/a> company; acquired by the healthcare-focused global private equity firm in 2020. The acquisition of CRI is the 8th<\/sup> acquisition of NAMSA since being an ARCHIMED company.<\/p>\n

\nABOUT NAMSA<\/span><\/b><\/p>\n

\nHelping medical device Sponsors improve healthcare since 1967, NAMSA is the world\u2019s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients\u2019 products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry\u2019s premier, trusted partner for successful development and commercialization outcomes. Web: www.namsa.com<\/a><\/p>\n

\nAbout CRI<\/span><\/b><\/p>\n

\nA research institute driven by its staff and their ideas: longstanding professional experience and scientific expertise evidenced by studies with high-level publications combined with motivation and team spirit. Conducting non-mainstream medical research is CRI\u2019s profession – with unconventional impulses, a dynamic fresh approach, and new ideas. The Institute is in the heart of Bavaria with a view over Munich towards the mountains where our staff members are working \u2013 creative and innovative in their approach, but strictly in line with international standards. Web: www.cri-muc.eu\/<\/a><\/p>\n

\nAbout ARCHIMED<\/span><\/b><\/p>\n

\nWith offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages \u20ac8 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EUR\u00caKA Foundation. Web: www.archimed.group<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nNAMSA Media Contact<\/span><\/b>
Christopher Rupp
\n
Vice President, Global Marketing & Commercial Operations
\n
Email: crupp@namsa.com<\/a><\/p>\n

CRI Media Contact<\/span><\/b>
Thomas Fetsch
\n
CEO
\n
Email: t.fetsch@cri-muc.eu<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOLEDO, Ohio & MUNICH–(BUSINESS WIRE)–#CRO—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of CRI – The Clinical Research Institute, a German-based full service CRO. Founded in 2011, CRI\u2019s mission is to provide the European MedTech market complete clinical research solutions to accelerate scientific outcomes to their … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57761","6":"format-standard","7":"category-industry"},"yoast_head":"\nNAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOLEDO, Ohio & MUNICH–(BUSINESS WIRE)–#CRO—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of CRI – The Clinical Research Institute, a German-based full service CRO. Founded in 2011, CRI\u2019s mission is to provide the European MedTech market complete clinical research solutions to accelerate scientific outcomes to their ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-18T11:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230718939367\/en\/667069\/21\/NamsaLogo-1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe\",\"datePublished\":\"2023-07-18T11:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/\"},\"wordCount\":728,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230718939367\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/\",\"name\":\"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230718939367\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\",\"datePublished\":\"2023-07-18T11:04:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230718939367\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230718939367\\\/en\\\/667069\\\/21\\\/NamsaLogo-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/","og_locale":"en_US","og_type":"article","og_title":"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe - Pharma Trend","og_description":"TOLEDO, Ohio & MUNICH–(BUSINESS WIRE)–#CRO—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of CRI – The Clinical Research Institute, a German-based full service CRO. Founded in 2011, CRI\u2019s mission is to provide the European MedTech market complete clinical research solutions to accelerate scientific outcomes to their ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/","og_site_name":"Pharma Trend","article_published_time":"2023-07-18T11:04:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230718939367\/en\/667069\/21\/NamsaLogo-1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe","datePublished":"2023-07-18T11:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/"},"wordCount":728,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230718939367\/en\/667069\/21\/NamsaLogo-1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/","url":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/","name":"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230718939367\/en\/667069\/21\/NamsaLogo-1.jpg","datePublished":"2023-07-18T11:04:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230718939367\/en\/667069\/21\/NamsaLogo-1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230718939367\/en\/667069\/21\/NamsaLogo-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/namsa-acquires-german-based-cri-to-expand-clinical-research-and-geographic-reach-across-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NAMSA Acquires German Based CRI to Expand Clinical Research and Geographic Reach Across Europe"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57761"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57761\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}